Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy.

PURPOSE To evaluate intensity-modulated whole pelvis radiotherapy (IM-WPRT) (with bone marrow [BM] as a planning constraint) as a means to reduce the volume of pelvic BM irradiated. METHODS AND MATERIALS Ten women with cervical or endometrial cancer previously treated using IM-WPRT were selected for this analysis. Using the treatment planning CT scan, the clinical target volume was defined to encompass the gross tumor, parametrial tissues, uterus (if present), and regional lymph nodes. The clinical target volume was expanded by a 1-cm margin to form the planning target volume (PTV). The bladder, rectum, small bowel, and pelvic BM were delineated in each patient. Three plans were created for each patient: a standard four-field WPRT plan, an IM-WPRT treatment plan designed to conform the dose to the PTV while minimizing dose to the normal tissues (excluding BM), and a BM-sparing (BMS) IM-WPRT plan that included the BM as an additional treatment planning constraint. Dose-volume histograms for the PTV, small bowel, and BM were compared for each patient. RESULTS For each of the 10 patients, BMS IM-WPRT treatment plans demonstrated a significant reduction of the volume of BM receiving >40% (18 Gy) of the prescription dose (45 Gy) compared with both IM-WPRT and four-field treatment. On average, BMS IM-WPRT resulted in only 60% of the BM volume irradiated to >50% of the dose compared with 87.4% (p <0.001) of the BM volume in a four-field plan and 75.7% (p < 0.003) of the volume in an IM-WPRT plan. Furthermore, the BMS IM-WPRT plans resulted in significant sparing of all other normal tissues that was comparable to the original IM-WPRT. In all 10 cases, the BMS IM-WPRT treatment plan did not result in any significant differences in the PTV and small bowel dose-volume histograms compared with the IM-WPRT treatment plans. CONCLUSION BMS IM-WPRT significantly reduces the volume of pelvic BM irradiated compared with conventional WPRT. In addition, BMS IM-WPRT did not compromise the improvements previously seen in IM-WPRT treatment plans that did not consider BM. Clinical studies are necessary to assess the significance of BMS IM-WPRT in reducing hematologic toxicity.

[1]  J. Roeske,et al.  Late rectal sequelae following definitive radiation therapy for carcinoma of the uterine cervix: a dosimetric analysis. , 1997, International journal of radiation oncology, biology, physics.

[2]  B. Maldague,et al.  Magnetic resonance imaging of the normal bone marrow , 1998, Skeletal Radiology.

[3]  B N Bundy,et al.  Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. , 1999, The New England journal of medicine.

[4]  J. Purdy,et al.  Radiation therapy alone in the treatment of carcinoma of the uterine cervix. II. Analysis of complications , 1984, Cancer.

[5]  John C Roeske,et al.  Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. , 2002, International journal of radiation oncology, biology, physics.

[6]  R. E. Ellis,et al.  The distribution of active bone marrow in the adult. , 1961, Physics in medicine and biology.

[7]  B. Emami,et al.  Comparison of IMRT with 3-D CRT for gynecologic malignancies , 2001 .

[8]  Srinivasan Vijayakumar,et al.  Analysis of weekly complete blood counts in patients receiving standard fractionated partial body radiation therapy. , 1995, International journal of radiation oncology, biology, physics.

[9]  J. Roeske,et al.  Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies. , 2000, International journal of radiation oncology, biology, physics.

[10]  J. Roeske,et al.  Intensity-modulated radiation therapy in gynecologic malignancies. , 2002, Current treatment options in oncology.

[11]  John C Roeske,et al.  Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. , 2002, International journal of radiation oncology, biology, physics.

[12]  B N Bundy,et al.  Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. , 1999, The New England journal of medicine.

[13]  C. Compton,et al.  Carcinoma of the anal canal. , 2000, The New England journal of medicine.

[14]  J Sullivan,et al.  Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. , 1995, International journal of radiation oncology, biology, physics.

[15]  D. Hallahan,et al.  Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease. , 1995, International journal of radiation oncology, biology, physics.

[16]  J. Roeske,et al.  Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. , 2001, Gynecologic oncology.

[17]  M. van Glabbeke,et al.  Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Yahalom.  Integrating radiotherapy into bone marrow transplantation programs for Hodgkin's disease. , 1995, International journal of radiation oncology, biology, physics.

[19]  D Low,et al.  Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. , 2001, International journal of radiation oncology, biology, physics.